Abstract 1835P
Background
The study was aimed to evaluate the effect of UA level on the 30-day mortality of patients admitted to the hospital with a complaint of FEN. The secondary aim was to evaluate the use of combining serum UA levels with the MASCC score.
Methods
Between January 2016 and May 2019, the files of patients with a diagnosis of febrile neutropenia were retrospectively evaluated, the data of MASCC risk score and serum UA levels at the time of admission were recorded. All patients, who received at least one course of chemotherapy and were diagnosed with febrile neutropenia (FEN), were included in the study population. Patients were divided into four subgroups according to the low/high MASCC risk score and normal/increased level of UA. The 30-day mortality rates of these four groups were compared. The clinical parameters that may affect mortality of FEN were also evaluated.
Results
A total of one hundred and eighteen febrile neutropenia (N = 118) episodes were included in the study and 17 (14%) of these patients died. While this rate is 23% in the high-risk group according to the MASCC score, it is 7% in the low-risk group (p 0.011). The 30-day mortality rate of patients whose level of UA higher than normal ≥ 7 mg/dl compared with UA level normal patients were 50% vs 11%, respectively (p < 0.001 ). In multivariate analysis of the parameters that significantly effect the 30.th day MASCC risk score (OR: 4.28, CI 95% 1.19-15.39, p=0.013) and having a level of serum UA > 7 mg/dl (OR: 4,46, CI 95% 1.19-15.38, p=0.032) was significantly increased the risk of in 30-day mortality of FEN. The rate of 30-day mortality of FEN was 100% in patients with low MASCC risk score and UA level compared with 50% in the MASCC risk score high and high UA level group and the difference was statistically significant (p <0.001).
Conclusions
Increased level of UA at time of FEN diagnosis was independently associated with increased rate of 30.th day mortality of FEN. The combination of the MASCC risk score with serum UA level might be thoroughly predicts the 30.th day mortality of FEN.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Osman Sütcüoğlu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.